TGFB1 and hepatocellular carcinoma: In patients with advanced hepatocellular carcinoma treated with the first clinically available ALK5 inhibitor, galunisertib (1)13, an approximately two-fold longer overall survival was observed in patients having a TGF-β1 response compared to patients who did not have a TGF-β1 response.14